Rawshani, A. et al. Mortality and cardiovascular disease in Type 1 and Type 2 diabetes. Nw Eng. J. Med. 376, 1407–1418 (2017).
Pearson-Stuttard, J. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrin. 9, 165–173 (2021).
Nathan, D. M. et al. Glycemia Reduction in Type 2 Diabetes – Glycemic Outcomes. N Engl J Med 387, 1063–1074 (2022).
I. D. F. Diabetes Atlas. Diabetes around the world in 2021, https://diabetesatlas.org/ (2021).
van Dieren, S. et al. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with Type 2 diabetes. Diabetologia 54, 264–270 (2011).
Szymonifka, J. et al. Cardiovascular disease risk prediction for people with type 2 diabetes in a population-based cohort and in electronic health record data. JAMIA Open 3, 583–592 (2020).
Ho, J. C. et al. Evaluation of available risk scores to predict multiple cardiovascular complications for patients with type 2 diabetes mellitus using electronic health records. Comp. Methods Prog. Biomed. Update 3, 100087 (2023).
Chung, W. K. et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetes Care 43, 1617–1635 (2020).
Nolan, J. J. et al. ADA/EASD precision medicine in diabetes initiative: an international perspective and future vision for precision medicine in diabetes. Diabetes Care 45, 261–266 (2022).
Tobias, D. K. et al. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat. Med. 29, 2438–2457 (2023).
Damen, J. A. et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ 353, i2416 (2016).
Zhiting, G. et al. Cardiovascular disease risk prediction models in the Chinese population- a systematic review and meta-analysis. BMC Public Health 22, 1608 (2022).
Damen, J. A. et al. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. BMC Med. 17, 109 (2019).
Romero-Cabrera, J. L., Ankeny, J., Fernández-Montero, A., Kales, S. N. & Smith, D. L. A systematic review and meta-analysis of advanced biomarkers for predicting incident cardiovascular disease among asymptomatic middle-aged adults. Int. J. Mol. Sci. 23, 13540 (2022).
van Holten, T. C. et al. Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS One 8, e62080 (2013).
Guasti, L. et al. TMAO as a biomarker of cardiovascular events: a systematic review and meta-analysis. Intern. Emerg. Med. 16, 201–207 (2021).
Rienks, J., Barbaresko, J. & Nöthlings, U. Association of polyphenol biomarkers with cardiovascular disease and mortality risk: a systematic review and meta-analysis of observational studies. Nutrients 9, 415 (2017).
Gohel, V., Jones, J. A. & Wehler, C. J. Salivary biomarkers and cardiovascular disease: a systematic review. Clin. Chem. Lab Med. 56, 1432–1442 (2018).
Kanbay, M. et al. Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int. Urol. Nephrol. 48, 2029–2042 (2016).
Heianza, Y., Ma, W., Manson, J. E., Rexrode, K. M. & Qi, L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies. J. Am. Heart Assoc. 6, e004947 (2017).
Wallace, T. C., Slavin, M. & Frankenfeld, C. L. Systematic review of anthocyanins and markers of cardiovascular disease. Nutrients 8, 32 (2016).
Emadian, A., Andrews, R. C., England, C. Y., Wallace, V. & Thompson, J. L. The effect of macronutrients on glycaemic control: a systematic review of dietary randomised controlled trials in overweight and obese adults with type 2 diabetes in which there was no difference in weight loss between treatment groups. Br. J. Nutr. 114, 1656–1666 (2015).
Yun, H., Noh, N. I. & Lee, E. Y. Genetic risk scores used in cardiovascular disease prediction models: a systematic review. Rev. Cardiovasc. Med. 23, 8 (2022).
Jeong, E. G. et al. Depth and combined infection is important predictor of lower extremity amputations in hospitalized diabetic foot ulcer patients. Korean J. Intern Med. 33, 952–960 (2018).
Lin, J. S. et al. Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US preventive services task force. Jama 320, 281–297 (2018).
Hlatky, M. A. et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119, 2408–2416 (2009).
Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).
Wells GA, S. B., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
Viechtbauer, W. Conducting meta-analyses in R with the metafor Package. J. Stat. Soft. 36, 1–48 (2010).
Owens, D. K. et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions–agency for healthcare research and quality and the effective health-care program. J. Clin. Epidemiol. 63, 513–523 (2010).
Aromataris E. et al. JBI Manual for Evidence Synthesis. JBI, https://doi.org/10.46658/JBIMES-20-01 (2020).
Aboyans, V. et al. The prognosis of diabetic patients with high ankle-brachial index depends on the coexistence of occlusive peripheral artery disease. J. Vasc. Surg. 53, 984–991 (2011).
Abu-Lebdeh, H. S., Hodge, D. O. & Nguyen, T. T. Predictors of macrovascular disease in patients with Type 2 diabetes mellitus. Mayo Clin. Proc. 76, 707–712 (2001).
Afarideh, M. et al. Complex association of serum alanine aminotransferase with the risk of future cardiovascular disease in Type 2 diabetes. Atherosclerosis 254, 42–51 (2016).
Afsharian, S. et al. Risk factors for cardiovascular disease and mortality events in adults with Type 2 diabetes- a 10-year follow-up: Tehran lipid and glucose study. Diabetes Metab. Res. Rev. 32, 596–606 (2016).
Alele, J. D., Luttrell, L. M., Hollis, B. W., Luttrell, D. K. & Hunt, K. J. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis 228, 502–507 (2013).
Alkhalaf, A. et al. Sex specific association between carnosinase gene CNDP1 and cardiovascular mortality in patients with Type 2 diabetes (ZODIAC-22). J. Nephrol. 28, 201–207 (2015).
Anand, D. V., Lahiri, A., Lim, E., Hopkins, D. & Corder, R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated Type 2 diabetic subjects. J. Am. Coll. Cardiol. 47, 1850–1857 (2006).
Anand, D. V. et al. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur. Heart J. 27, 713–721 (2006).
Anavekar, N. S. et al. Predictors of cardiovascular events in patients with Type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl, 66 S50-55 (2004).
Angiolillo, D. J. et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50, 1541–1547 (2007).
Anyanwagu, U., Donnelly, R. & Idris, I. Albuminuria regression and all-cause mortality among insulin-treated patients with Type 2 Diabetes: analysis of a large UK primary care Cohort. Am. J. Nephrol. 49, 146–155 (2019).
Apperloo, E. M., Pena, M. J., de Zeeuw, D., Denig, P. & Heerspink, H. J. L. Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with Type 2 diabetes: a primary care cohort study. Diabetes Obes. Metab. 20, 1377–1383 (2018).
Araki, S. et al. Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care 36, 1248–1253 (2013).
Avogaro, A. et al. Incidence of coronary heart disease in Type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 30, 1241–1247 (2007).
Azab, B., Chainani, V., Shah, N. & McGinn, J. T. Neutrophil-lymphocyte ratio as a predictor of major adverse cardiac events among diabetic population: a 4-year follow-up study. Angiology 64, 456–465 (2013).
Azevedo, M. J. et al. Value of diagnostic tools for myocardial ischemia used in routine clinical practice to predict cardiac events in patients with type 2 diabetes mellitus: a prospective study. Arq. Bras. Endocrinol. Metab. 50, 46–52 (2006).
Bacci, S. et al. The ENPP1 Q121 variant predicts major cardiovascular events in high-risk individuals: evidence for interaction with obesity in diabetic patients. Diabetes 60, 1000–1007 (2011).
Backhaus, S. J. et al. Cardiac magnetic resonance myocardial feature tracking for optimized risk assessment after acute myocardial infarction in patients with Type 2 Diabetes. Diabetes 69, 1540–1548 (2020).
Basu, S. et al. Validation of risk Equations for complications of Type 2 diabetes (RECODe) using individual participant data from diverse longitudinal Cohorts in the U.S. Diabetes Care 41, 586–595 (2018).
Basu, S., Sussman, J. B., Berkowitz, S. A., Hayward, R. A. & Yudkin, J. S. Development and validation of risk equations for complications Of Type 2 diabetes (RECODe) using individual participant data from randomised trials. Lancet Diabetes Endocrinol. 5, 788–798 (2017).
Bates, R. E. et al. Impact of stress testing for coronary artery disease screening in asymptomatic patients with diabetes mellitus: a community-based study in olmsted county, Minnesota. Mayo Clin. Proc. 91, 1535–1544 (2016).
Beaney, K. E. et al. Variant rs10911021 that associates with coronary heart disease in type 2 diabetes, is associated with lower concentrations of circulating HDL cholesterol and large HDL particles but not with amino acids. Cardiovasc. Diabetol. 15, 115 (2016).
Beilin, J., Stanton, K. G., McCann, V. J., Knuiman, M. W. & Divitini, M. L. Microalbuminuria in Type 2 diabetes: an independent predictor of cardiovascular mortality. Aust. N Z J. Med. 26, 519–525 (1996).
Bell, K. J. L. et al. Prognostic impact of systolic blood pressure variability in people with diabetes. PLoS One 13, e0194084 (2018).
Berkelmans, G. F. N. et al. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500,000 patients with Type 2 diabetes mellitus. Eur Heart J 40, 2899–2906 (2019).
Bernard, S. et al. Relation between XbA1 apolipoprotein B gene polymorphism and cardiovascular risk in a Type 2 diabetic cohort. Atherosclerosis 175, 177–181 (2004).
Bernard, S. et al. Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic Type 2 diabetic subjects. Diabetes Care 28, 1158–1162 (2005).
Bianco, H. T. et al. Relevance of target-organ lesions as predictors of mortality in patients with diabetes mellitus. Arq Bras Cardiol 103, 272–281 (2014).
Biscetti, F. et al. Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study. Cardiovasc. Diabetol. 19, 170 (2020).
Bonito, B., Silva, A. P., Rato, F., Santos, N. & Neves, P. L. Resistin as a predictor of cardiovascular hospital admissions and renal deterioration in diabetic patients with chronic kidney disease. J. Diabetes Complications 33, 107422 (2019).
Bosevski, M., Borozanov, V., Tosev, S. & Georgievska-Ismail, L. Is assessment of peripheral endothelial dysfunction useful tool for risk stratification of Type 2 diabetic patients with manifested coronary artery disease? Int. J. Cardiol. 131, 290–292 (2009).
Bouchi, R. et al. Fluctuations in HbA1c are associated with a higher incidence of cardiovascular disease in Japanese patients with Type 2 diabetes. J. Diabetes Invest. 3, 148–155 (2012).
Brownrigg, J. R. et al. Microvascular disease and risk of cardiovascular events among individuals with Type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 4, 588–597 (2016).
Bruce, D. G., Davis, W. A., Starkstein, S. E. & Davis, T. M. A prospective study of depression and mortality in patients with Type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 48, 2532–2539 (2005).
Bruno, G., Barutta, F., Landi, A., Cavallo Perin, P. & Gruden, G. NT-proBNP linking low-moderately impaired renal function and cardiovascular mortality in diabetic patients: the population-based Casale Monferrato Study. PLoS One 9, e114855 (2014).
Bruno, G. et al. N-terminal probrain natriuretic peptide is a stronger predictor of cardiovascular mortality than C-reactive protein and albumin excretion rate in elderly patients with type 2 diabetes: the Casale Monferrato population-based study. Diabetes Care 36, 2677–2682 (2013).
Bruno, G. et al. Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in Type 2 diabetes: the Casale Monferrato Study. Diabetologia 48, 427–434 (2005).
Bruno, G. et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in Type 2 diabetes: the Casale Monferrato Study. Diabetes Care 27, 2689–2694 (2004).
Burgess, D. C. et al. Incidence and predictors of silent myocardial infarction in Type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur. Heart J. 31, 92–99 (2010).
Busch, M. et al. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am. J. Kidney Dis. 48, 571–579 (2006).
Böger, C. A. et al. RANTES gene polymorphisms predict all-cause and cardiac mortality in Type 2 diabetes mellitus hemodialysis patients. Atherosclerosis 183, 121–129 (2005).
Cardona, A. et al. Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis. BMJ Open Diabetes Res Care 7, e000718 (2019).
Cardoso, C. R., Ferreira, M. T., Leite, N. C. & Salles, G. F. Prognostic impact of aortic stiffness in high-risk Type 2 diabetic patients: the Rio deJaneiro Type 2 Diabetes Cohort Study. Diabetes Care 36, 3772–3778 (2013).
Cardoso, C. R., Leite, N. C. & Salles, G. F. Prognostic importance of C-Reactive protein in high cardiovascular risk patients with Type 2 diabetes mellitus: the Rio de Janeiro Type 2 diabetes Cohort Study. J. Am. Heart Assoc. 5, e004554 (2016).
Cardoso, C. R., Salles, G. F. & Deccache, W. Prognostic value of QT interval parameters in Type 2 diabetes mellitus: results of a long-term follow-up prospective study. J. Diabetes Complications 17, 169–178 (2003).
Cardoso, C. R. L., Leite, N. C., Moram, C. B. M. & Salles, G. F. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with Type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc. Diabetol. 17, 33 (2018).
Cardoso, C. R. L., Leite, N. C. & Salles, G. F. Prognostic importance of visit-to-visit blood pressure variability for micro- and macrovascular outcomes in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc. Diabetol. 19, 50 (2020).
Cardoso, C. R. L., Salles, G. C., Leite, N. C. & Salles, G. F. Prognostic impact of carotid intima-media thickness and carotid plaques on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro Type 2 diabetes cohort study. Cardiovasc. Diabetol. 18, 2 (2019).
Carlsson, A. C. et al. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Ups J. Med. Sci. 125, 37–43 (2020).
Carlsson, A. C. et al. Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in Type 2 diabetes. Cardiovasc. Diabetol. 15, 40 (2016).
Carnethon, M. R. et al. Association of weight status with mortality in adults with incident diabetes. JAMA 308, 581–590 (2012).
Casiglia, E. et al. Cardiovascular mortality in non-insulin-dependent diabetes mellitus. A controlled study among 683 diabetics and 683 age- and sex-matched normal subjects. Eur. J. Epidemiol. 16, 677–684 (2000).
Cavalot, F. et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in Type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care 34, 2237–2243 (2011).
Cavalot, F. et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in Type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J. Clin. Endocrinol. Metab. 91, 813–819 (2006).
Cea Soriano, L., Johansson, S., Stefansson, B. & Rodríguez, L. A. Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with Type 2 diabetes: associations with renal function and cardiovascular risk factors. Cardiovasc. Diabetol. 14, 38 (2015).
Cederholm, J. et al. Risk prediction of cardiovascular disease in Type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care 31, 2038–2043 (2008).
Celis-Morales, C. A. et al. Associations between diabetes and both cardiovascular disease and all-cause mortality are modified by grip strength: evidence from UK Biobank, a prospective population-based Cohort study. Diabetes Care 40, 1710–1718 (2017).
Ceriello, A. et al. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial. Cardiovasc. Diabetol. 19, 176 (2020).
Cha, S. A. et al. Time- and frequency-domain measures of heart rate variability predict cardiovascular outcome in patients with Type 2 diabetes. Diabetes Res. Clin. Pract. 143, 159–169 (2018).
Cha, S. A. et al. Diabetic cardiovascular autonomic neuropathy predicts recurrent cardiovascular diseases in patients with Type 2 Diabetes. PLoS One 11, e0164807 (2016).
Chacko, K. M. et al. Heart rate recovery predicts mortality and cardiovascular events in patients with type 2 diabetes. Med. Sci. Sports Exerc. 40, 288–295 (2008).
Chan, J. C. et al. Premature mortality and comorbidities in young-onset diabetes: a 7-year prospective analysis. Am. J. Med. 127, 616–624 (2014).
Chang, C. W. et al. The first harmonic of radial pulse as an early predictor of silent coronary artery disease and adverse cardiac events in Type 2 diabetic patients. Cardiol. Res. Pract. 2018, 5128626 (2018).
Chang, L. H. et al. The ankle brachial index exhibits better association of cardiovascular prognosis than non-high-density lipoprotein cholesterol in Type 2 diabetes. Am. J. Med. Sci. 351, 492–498 (2016).
Chang, L. H. et al. Upstroke time per cardiac cycle is associated with cardiovascular prognosis in Type 2 diabetes. Endocr. Pract. 25, 1109–1116 (2019).
Charlton-Menys, V. et al. Apolipoproteins, cardiovascular risk and statin response in Type 2 diabetes: the collaborative atorvastatin diabetes study (CARDS). Diabetologia 52, 218–225 (2009).
Chen, H. S. et al. Subclinical hypothyroidism is a risk factor for nephropathy and cardiovascular diseases in Type 2 diabetic patients. Diabet. Med. 24, 1336–1344 (2007).
Chen, S. et al. The long-term effectiveness of metabolic control on cardiovascular disease in patients with diabetes in a real-world health care setting – A prospective diabetes management study. Prim. Care Diabetes 14, 274–281 (2020).
Cheng, F. et al. Shortened relative leukocyte telomere length is associated with prevalent and incident cardiovascular complications in Type 2 diabetes: analysis from the Hong Kong diabetes register. Diabetes Care 43, 2257–2265 (2020).
Christensen, P. K. et al. QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes. Scand J. Clin. Lab Invest. 60, 323–332 (2000).
Christiansen, M. S., Hommel, E., Magid, E. & Feldt-Rasmussen, B. Orosomucoid in urine predicts cardiovascular and over-all mortality in patients with Type II diabetes. Diabetologia 45, 115–120 (2002).
Christiansen, M. S., Hommel, E., Magid, E. & Feldt-Rasmussen, B. Orosomucoid in urine is a powerful predictor of cardiovascular mortality in normoalbuminuric patients with Type 2 diabetes at five years of follow-up. Diabetologia 48, 386–393 (2005).
Church, E. et al. Relationship between estimated glomerular filtration rate and incident cardiovascular disease in an ethnically diverse primary care cohort. N Z Med. J. 132, 11–26 (2019).
Chyun, D. A. et al. Autonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with Type 2 diabetes in the DIAD study. SAGE Open Med. 3, 2050312114568476 (2015).
Cioffi, G. et al. Usefulness of subclinical left ventricular midwall dysfunction to predict cardiovascular mortality in patients with Type 2 diabetes mellitus. Am. J. Cardiol. 113, 1409–1414 (2014).
Clarke, P. M. et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 47, 1747–1759 (2004).
Clarke, P. M. et al. Using the EQ-5D index score as a predictor of outcomes in patients with Type 2 diabetes. Med. Care 47, 61–68 (2009).
Cockcroft, J. R. et al. Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus. Am. J. Hypertens. 18, 1463–1467 (2005).
Colombo, M. et al. Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in Type 2 diabetes. Atherosclerosis 274, 182–190 (2018).
Cortigiani, L. et al. Prognostic meaning of coronary microvascular disease in type 2 diabetes mellitus: a transthoracic Doppler echocardiographic study. J. Am. Soc. Echocardiogr. 27, 742–748 (2014).
Cosson, E. et al. Cardiovascular risk prediction is improved by adding asymptomatic coronary status to routine risk assessment in type 2 diabetic patients. Diabetes Care 34, 2101–2107 (2011).
Cournot, M. et al. Circulating concentrations of redox biomarkers do not improve the prediction of adverse cardiovascular events in patients with Type 2 diabetes mellitus. J Am Heart Assoc 7, e007397 (2018).
Cox, A. J. et al. Prediction of mortality using a multi-bed vascular calcification score in the Diabetes Heart Study. Cardiovasc. Diabetol. 13, 160 (2014).
Cox, A. J. et al. Genetic risk score associations with cardiovascular disease and mortality in the Diabetes Heart Study. Diabetes Care 37, 1157–1164 (2014).
Cox, A. J. et al. Usefulness of biventricular volume as a predictor of mortality in patients with diabetes mellitus (from the Diabetes Heart Study). Am. J. Cardiol. 111, 1152–1158 (2013).
Cui, N. H., Yang, J. M., Liu, X. & Wang, X. B. Poly(ADP-Ribose) Polymerase activity and coronary artery disease in Type 2 Diabetes mellitus: an observational and bidirectional mendelian randomization study. Arterioscler Thromb. Vasc. Biol. 40, 2516–2526 (2020).
Daka, B. et al. Low concentrations of serum testosterone predict acute myocardial infarction in men with Type 2 diabetes mellitus. BMC Endocr Disord 15, 35 (2015).
Davis, T. M., Coleman, R. L. & Holman, R. R. Ethnicity and long-term vascular outcomes in Type 2 diabetes: a prospective observational study (UKPDS 83). Diabet Med 31, 200–207 (2014).
Davis, W. A., Colagiuri, S. & Davis, T. M. Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with Type 2 diabetes from the Fremantle Diabetes Study. Med. J. Aust. 190, 180–184 (2009).
Davis, W. A., Hellbusch, V., Hunter, M. L., Bruce, D. G. & Davis, T. M. E. Contemporary cardiovascular risk assessment for Type 2 diabetes including heart failure as an outcome: The fremantle diabetes study phase ii. J. Clin. Med. 9, 1428 (2020).
Davis, W. A., Knuiman, M. W. & Davis, T. M. An Australian cardiovascular risk equation for Type 2 diabetes: the Fremantle Diabetes Study. Intern. Med. J. 40, 286–292 (2010).
Dayan, A. et al. Coronary calcium score, albuminuria and inflammatory markers in Type 2 diabetic patients: associations and prognostic implications. Diabetes Res. Clin. Pract. 98, 98–103 (2012).
de Galan, B. E. et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with Type 2 diabetes: the action in diabetes and vascular disease: preterax and diamicron modified release controlled evaluation (ADVANCE) trial. Diabetologia 52, 2328–2336 (2009).
De Lorenzo, A., Lima, R. S., Siqueira-Filho, A. G. & Pantoja, M. R. Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with diabetes mellitus and no known coronary artery disease. Am. J. Cardiol. 90, 827–832 (2002).
de Santiago, A., García-Lledó, A., Ramos, E. & Santiago, C. Prognostic value of ECGs in patients with Type-2 diabetes mellitus without known cardiovascular disease. Rev. Esp. Cardiol. 60, 1035–1041 (2007).
de Vries, T. I. et al. Normal-range thyroid-stimulating hormone levels and cardiovascular events and mortality in Type 2 diabetes. Diabetes Res. Clin. Pract. 157, 107880 (2019).
Djaileb, L. et al. Prognostic value of SPECT myocardial perfusion entropy in high-risk Type 2 diabetic patients. Eur. J. Nucl. Med. Mol. Imaging 48, 1813–1821 (2021).
Doney, A. S. et al. The FTO gene is associated with an atherogenic lipid profile and myocardial infarction in patients with Type 2 diabetes: a genetics of diabetes audit and research study in Tayside Scotland (Go-DARTS) study. Circ. Cardiovasc. Genet. 2, 255–259 (2009).
Doney, A. S., Lee, S., Leese, G. P., Morris, A. D. & Palmer, C. N. Increased cardiovascular morbidity and mortality in Type 2 diabetes is associated with the glutathione S transferase theta-null genotype: a Go-DARTS study. Circulation 111, 2927–2934 (2005).
Doney, A. S. F. et al. Association of common variation in the PPARA gene with incident myocardial infarction in individuals with Type 2 diabetes: A Go-DARTS study. Nuclear Receptor 3, 4 (2005).
Donnan, P. T., Donnelly, L., New, J. P. & Morris, A. D. Derivation and validation of a prediction score for major coronary heart disease events in a U.K. Type 2 diabetic population. Diabetes Care 29, 1231–1236 (2006).
Drinkwater, J. J. et al. Retinopathy predicts stroke but not myocardial infarction in Type 2 diabetes: the Fremantle Diabetes Study Phase II. Cardiovasc. Diabetol. 19, 43 (2020).
Drury, P. L. et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in Type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 54, 32–43 (2011).
Duan, J. G. et al. Long-term risk of cardiovascular disease among Type 2 diabetic patients with asymptomatic intracranial atherosclerosis: a prospective cohort study. PLoS One 9, e106623 (2014).
Duan, J. G. et al. Sex differences in epidemiology and risk factors of acute coronary syndrome in Chinese patients with Type 2 diabetes: a long-term prospective cohort study. PLoS One 10, e0122031 (2015).
Eguchi, K., Hoshide, S. & Kario, K. Target home morning SBP be below 125 mmHg in Type 2 diabetes patients. J. Hypertens. 36, 1284–1290 (2018).
Eguchi, K. et al. Differential impact of left ventricular mass and relative wall thickness on cardiovascular prognosis in diabetic and nondiabetic hypertensive subjects. Am. Heart J. 154, 79.e79–15 (2007).
Eguchi, K. et al. Night time blood pressure variability is a strong predictor for cardiovascular events in patients with Type 2 diabetes. Am. J. Hypertens. 22, 46–51 (2009).
Eguchi, K. et al. Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without Type 2 diabetes. Am. J. Hypertens. 21, 443–450 (2008).
Eguchi, K. et al. Increased heart rate variability during sleep is a predictor for future cardiovascular events in patients with Type 2 diabetes. Hypertens. Res. 33, 737–742 (2010).
Eijkelkamp, W. B. et al. Renal function and risk for cardiovascular events in Type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. J. Hypertens. 25, 871–876 (2007).
Eliasson, B. et al. Clinical usefulness of different lipid measures for prediction of coronary heart disease in Type 2 diabetes: a report from the Swedish National Diabetes Register. Diabetes Care 34, 2095–2100 (2011).
Elkeles, R. S. et al. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with Type 2 diabetes: the PREDICT study. Eur. Heart J. 29, 2244–2251 (2008).
Elley, C. R., Kenealy, T., Robinson, E. & Drury, P. L. Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. Diabet Med. 25, 1295–1301 (2008).
Elley, C. R., Robinson, E., Kenealy, T., Bramley, D. & Drury, P. L. Derivation and validation of a new cardiovascular risk score for people with Type 2 diabetes: the new zealand diabetes cohort study. Diabetes Care 33, 1347–1352 (2010).
Estacio, R. O., Dale, R. A., Schrier, R. & Krantz, M. J. Relation of reduction in urinary albumin excretion to ten-year cardiovascular mortality in patients with Type 2 diabetes and systemic hypertension. Am. J. Cardiol. 109, 1743–1748 (2012).
Everett, B. M. et al. Troponin and cardiac events in stable ischemic heart disease and diabetes. N. Engl. J. Med. 373, 610–620 (2015).
Fadini, G. P. et al. p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications. Cardiovasc. Diabetol. 17, 16 (2018).
Fadini, G. P., Rigato, M., Cappellari, R., Bonora, B. M. & Avogaro, A. Long-term prediction of cardiovascular outcomes by circulating CD34+ and CD34+CD133+ stem cells in patients with Type 2 diabetes. Diabetes Care 40, 125–131 (2017).
Faghihi-Kashani, S. et al. Fasting hyperinsulinaemia and 2-h glycaemia predict coronary heart disease in patients with Type 2 diabetes. Diabetes Metab. 42, 55–61 (2016).
Faglia, E. et al. Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease: 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes (MiSAD). Diabetes Care 25, 2032–2036 (2002).
Ferrarezi, D. A. et al. Allelic variations of the vitamin D receptor (VDR) gene are associated with increased risk of coronary artery disease in Type 2 diabetics: the DIABHYCAR prospective study. Diabetes Metab 39, 263–270 (2013).
Filippella, M. et al. Ankle brachial pressure index usefulness as predictor factor for coronary heart disease in diabetic patients. J. Endocrinol. Invest. 30, 721–725 (2007).
Florkowski, C. M., Scott, R. S., Coope, P. A. & Moir, C. L. Predictors of mortality from Type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study. Diabetes Res Clin Pract 53, 113–120 (2001).
Folsom, A. R., Chambless, L. E., Duncan, B. B., Gilbert, A. C. & Pankow, J. S. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care 26, 2777–2784 (2003).
Fox, C. S., Sullivan, L., D’Agostino, R. B. Sr & Wilson, P. W. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diabetes Care 27, 704–708 (2004).
Fragoso, A., Mendes, F., Silva, A. P. & Neves, P. L. Insulin resistance as a predictor of cardiovascular morbidity and end-stage renal disease. J. Diabetes Complications 29, 1098–1104 (2015).
Freemantle, N., Danchin, N., Calvi-Gries, F., Vincent, M. & Home, P. D. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin. Diabetes Obes. Metab. 18, 152–158 (2016).
Friedman, A. N., Hunsicker, L. G., Selhub, J. & Bostom, A. G. Total plasma homocysteine and arteriosclerotic outcomes in Type 2 diabetes with nephropathy. J. Am. Soc. Nephrol. 16, 3397–3402 (2005).
Fukushima, H. et al. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. J. Am. Coll. Cardiol. 43, 2219–2224 (2004).
Fuller, J. H., Stevens, L. K. & Wang, S. L. Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes. Diabetologia 44, S54–64 (2001).
Fumisawa, Y. et al. Systematic analysis of risk factors for coronary heart disease in Japanese patients with Type 2 diabetes: a matched case-control study. J. Atheroscler. Thromb. 19, 918–923 (2012).
Gasior, M. et al. Effect of blood glucose levels on prognosis in acute myocardial infarction in patients with and without diabetes, undergoing percutaneous coronary intervention. Cardiol. J. 15, 422–430 (2008).
Gazzaruso, C. et al. Transcutaneous oxygen tension as a potential predictor of cardiovascular events in Type 2 diabetes: comparison with ankle-brachial index. Diabetes Care 36, 1720–1725 (2013).
Gazzaruso, C. et al. Lipoprotein(a), apolipoprotein(a) polymorphism and restenosis after intracoronary stent placement in Type 2 diabetic patients. J. Diabetes Complications 17, 135–140 (2003).
Gazzaruso, C. et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J. Am. Coll. Cardiol. 51, 2040–2044 (2008).
Georgoulias, P. et al. Long-term prognostic value of heart-rate recovery after treadmill testing in patients with diabetes mellitus. Int. J. Cardiol. 134, 67–74 (2009).
Gimeno-Orna, J. A., Lou-Arnal, L. M., Boned-Juliani, B. & Molinero-Herguedas, E. Mild renal insufficiency as a cardiovascular risk factor in non-proteinuric Type II diabetes. Diabetes Res. Clin. Pract. 64, 191–199 (2004).
Giorda, C. B. et al. Recurrence of cardiovascular events in patients with Type 2 diabetes: epidemiology and risk factors. Diabetes Care 31, 2154–2159 (2008).
Giovacchini, G. et al. Microalbuminuria predicts silent myocardial ischaemia in Type 2 diabetes patients. Eur. J. Nucl. Med. Mol. Imaging 40, 548–557 (2013).
Group, T. L. A. R. Prospective Association of GLUL rs10911021 with cardiovascular morbidity and mortality among individuals with Type 2 diabetes: The Look AHEAD Study. Diabetes 65, 297–302, (2015).
Guzder, R. N., Gatling, W., Mullee, M. A. & Byrne, C. D. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed Type 2 diabetes. Diabetologia 49, 49–55 (2006).
Guzder, R. N., Gatling, W., Mullee, M. A., Mehta, R. L. & Byrne, C. D. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. Diabet Med 22, 554–562 (2005).
Hadaegh, F. et al. Electrocardiography-defined silent CHD and risk of cardiovascular events among diabetic patients in a Middle Eastern population. Eur. J. Prev. Cardiol. 19, 1227–1233 (2012).
Hadjadj, S. et al. Prognostic value of the insertion/deletion polymorphism of the ACE gene in Type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabetes. Diabetes Care 31, 1847–1852 (2008).
Hage, F. G. et al. The heart rate response to adenosine: a simple predictor of adverse cardiac outcomes in asymptomatic patients with type 2 diabetes. Int. J. Cardiol. 167, 2952–2957 (2013).
Halon, D. A. et al. Coronary computed tomography (CT) angiography as a predictor of cardiac and noncardiac vascular events in asymptomatic Type 2 diabetics: a 7-year population-based Cohort Study. J. Am. Heart Assoc. 5, e003226 (2016).
Halon, D. A. et al. Plaque morphology as predictor of late plaque events in patients with asymptomatic Type 2 diabetes. A Long-Term Observational Study. JACC Cardiovasc. Imaging 12, 1353–1363 (2019).
Hamada, S. & Gulliford, M. C. Multiple risk factor control, mortality and cardiovascular events in Type 2 diabetes and chronic kidney disease: a population-based cohort study. BMJ Open 8, e019950 (2018).
Hanefeld, M. et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39, 1577–1583 (1996).
Hata, J. et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with Type 2 diabetes mellitus: the ADVANCE trial. Circulation 128, 1325–1334 (2013).
Hayashi, T. et al. Metabolic predictors of ischemic heart disease and cerebrovascular attack in elderly diabetic individuals: difference in risk by age. Cardiovasc Diabetol 12, 10 (2013).
Hayes, A. J., Leal, J., Gray, A. M., Holman, R. R. & Clarke, P. M. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 56, 1925–1933 (2013).
He, Q., Pan, J., Wang, L., Fang, Y. & Hu, R. Prospective study: Aldehyde dehydrogenase 2 gene is associated with cardio-cerebrovascular complications in Type 2 diabetes patients. J. Diabetes Investig. 12, 1845–1854 (2021).
Heidari, B. et al. Assessment of serum 25-hydroxy vitamin D improves coronary heart disease risk stratification in patients with Type 2 diabetes. Am. Heart J. 170, 573–579.e575 (2015).
Heijmans, B. T. et al. Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis 149, 91–97 (2000).
Ho, J. S. et al. Association of the PPARG Pro12Ala polymorphism with Type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population. Diabetes Res. Clin. Pract. 97, 483–491 (2012).
Hoffmann, M. M., März, W., Genser, B., Drechsler, C. & Wanner, C. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study. Atherosclerosis 219, 659–662 (2011).
Hong, L. F. et al. Predictive value of non-fasting remnant cholesterol for short-term outcome of diabetics with new-onset stable coronary artery disease. Lipids Health Dis 16, 7 (2017).
Howard, B. V. et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler Thromb Vasc. Biol. 20, 830–835 (2000).
Hsieh, Y. T. et al. Subnormal estimated glomerular filtration rate strongly predict incident cardiovascular events in Type 2 diabetic chinese population with normoalbuminuria. Medicine (Baltimore) 95, e2200 (2016).
Hu, C. P. et al. Platelet distribution width on admission predicts in-stent restenosis in patients with coronary artery disease and Type 2 diabetes mellitus treated with percutaneous coronary intervention. Chin. Med. J. (Engl) 131, 757–763 (2018).
Huang, X. H. et al. Angiotensin-converting enzyme gene polymorphism is associated with coronary heart disease in non-insulin-dependent diabetic patients evaluated for 9 years. Metabolism 47, 1258–1262 (1998).
Hunt, K. J. et al. Plasma connective tissue growth factor (CTGF/CCN2) levels predict myocardial infarction in the veterans affairs diabetes trial (VADT) Cohort. Diabetes Care 41, 840–846 (2018).
Iijima, K. et al. Lower physical activity is a strong predictor of cardiovascular events in elderly patients with type 2 diabetes mellitus beyond traditional risk factors: the Japanese Elderly Diabetes Intervention Trial. Geriatr Gerontol Int 12, 77–87 (2012).
Ikeda, Y. et al. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol. 46, 239–242 (2009).
Irie, Y. et al. The utility of ultrasonic tissue characterization of carotid plaque in the prediction of cardiovascular events in diabetic patients. Atherosclerosis 230, 399–405 (2013).
Jeevarethinam, A. et al. Usefulness of carotid plaques as predictors of obstructive coronary artery disease and cardiovascular events in asymptomatic individuals with diabetes mellitus. Am. J. Cardiol. 121, 910–916 (2018).
Jha, D. et al. Prognostic role of soluble ST2 in acute coronary syndrome with diabetes. Eur. J. Clin. Invest. 48, e12994 (2018).
Jiang, R. et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 27, 1991–1997 (2004).
Jimenez-Corona, A. et al. Electrocardiographic abnormalities predict deaths from cardiovascular disease and ischemic heart disease in Pima Indians with Type 2 diabetes. Am. Heart J. 151, 1080–1086 (2006).
Jin, J. L. et al. Triglyceride glucose and haemoglobin glycation index for predicting outcomes in diabetes patients with new-onset, stable coronary artery disease: a nested case-control study. Ann. Med. 50, 576–586 (2018).
Johnston, S. S. et al. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with Type 2 diabetes. Diabetes Care 34, 1164–1170 (2011).
Juutilainen, A., Lehto, S., Suhonen, M., Rönnemaa, T. & Laakso, M. Thoracoabdominal calcifications predict cardiovascular disease mortality in Type 2 diabetic and nondiabetic subjects: 18-year follow-up study. Diabetes Care 33, 583–585 (2010).
Kamoi, K., Ito, T., Miyakoshi, M. & Minagawa, S. Usefulness of home blood pressure measurement in the morning in patients with type 2 diabetes: long-term results of a prospective longitudinal study. Clin. Exp. Hypertens. 32, 184–192 (2010).
Katakami, N. et al. Accumulation of oxidative stress-related gene polymorphisms and the risk of coronary heart disease events in patients with Type 2 diabetes–an 8-year prospective study. Atherosclerosis 235, 408–414 (2014).
Katakami, N. et al. Clinical utility of brachial-ankle pulse wave velocity in the prediction of cardiovascular events in diabetic patients. Cardiovasc. Diabetol. 13, 128 (2014).
Katakami, N. et al. Ultrasonic tissue characterization of carotid plaque improves the prediction of cardiovascular events in diabetic patients: a pilot study. Diabetes Care 35, 2640–2646 (2012).
Kawasaki, R. et al. Risk of cardiovascular diseases is increased even with mild diabetic retinopathy: the Japan diabetes complications study. Ophthalmology 120, 574–582 (2013).
Keavney, B. D. et al. UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM. Diabetologia 38, 948–952 (1995).
Keller, T. et al. Prognostic value of high-sensitivity versus conventional cardiac Troponin T assays among patients with Type 2 diabetes mellitus undergoing maintenance hemodialysis. Am. J. Kidney Dis. 71, 822–830 (2018).
Kenealy, T. et al. An association between ethnicity and cardiovascular outcomes for people with Type 2 diabetes in New Zealand. Diabet. Med. 25, 1302–1308 (2008).
Kengne, A. P. et al. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax. Diabetologia 53, 821–831 (2010).
Kengne, A. P. et al. Contemporary model for cardiovascular risk prediction in people with Type 2 diabetes. Eur. J. Cardiovasc. Prev. Rehabil. 18, 393–398 (2011).
Khalili, S., Hatami, M., Hadaegh, F., Sheikholeslami, F. & Azizi, F. Prediction of cardiovascular events with consideration of general and central obesity measures in diabetic adults: results of the 8.4-year follow-up. Metab. Syndr. Relat. Disord. 10, 218–224 (2012).
Kim, M. K. et al. Hemoglobin glycation index predicts cardiovascular disease in people with Type 2 diabetes mellitus: A 10-year longitudinal cohort study. J. Diabetes Complications 32, 906–910 (2018).
Koch, M., Kutkuhn, B., Grabensee, B. & Ritz, E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 12, 2603–2611 (1997).
Koo, B. K., Chung, W. Y. & Moon, M. K. Peripheral arterial endothelial dysfunction predicts future cardiovascular events in diabetic patients with albuminuria: a prospective cohort study. Cardiovasc. Diabetol. 19, 82 (2020).
Kuricová, K. et al. NOS3 894G>T polymorphism is associated with progression of kidney disease and cardiovascular morbidity in Type 2 diabetic patients: NOS3 as a modifier gene for diabetic nephropathy? Kidney Blood Press Res. 38, 92–98 (2013).
Lagani, V. et al. Development and validation of risk assessment models for diabetes-related complications based on the DCCT/EDIC data. J. Diabetes Complications 29, 479–487 (2015).
Lapin, B. R. et al. Pain in patients with Type 2 diabetes-related polyneuropathy is associated with vascular events and mortality. J. Clin. Endocrinol. Metab. 105, dgaa394 (2020).
Lau, K. K. et al. Prognostic implications of surrogate markers of atherosclerosis in low to intermediate risk patients with Type 2 diabetes. Cardiovasc. Diabetol. 11, 101 (2012).
Le Feuvre, C. L. et al. Stress myocardial scintigraphy and dobutamine echocardiography in the detection of coronary disease in asymptomatic patients with Type 2 diabetes. Diabetes Metab. 31, 135–142 (2005).
Lee, K. Y. et al. Computed tomography angiography images of coronary artery stenosis provide a better prediction of risk than traditional risk factors in asymptomatic individuals with Type 2 DIABETES: a long-term study of clinical outcomes. Diabetes Care 40, 1241–1248 (2017).
Lehto, S., Niskanen, L., Suhonen, M., Rönnemaa, T. & Laakso, M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc. Biol. 16, 978–983 (1996).
Lepojärvi, E. S. et al. Usefulness of highly sensitive troponin as a predictor of short-term outcome in patients with diabetes mellitus and stable coronary artery disease (from the ARTEMIS Study). Am. J. Cardiol. 117, 515–521 (2016).
Levy, A. P. et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J. Am. Coll. Cardiol. 40, 1984–1990 (2002).
Li, P. I., Wang, J. N. & Guo, H. R. A long-term quality-of-care score for predicting the occurrence of macrovascular diseases in patients with Type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 139, 72–80 (2018).
Li, W. P. et al. Pregnancy-associated plasma protein-A is a stronger predictor for adverse cardiovascular outcomes after acute coronary syndrome in Type-2 diabetes mellitus. Cardiovasc. Diabetol. 16, 45 (2017).
Liao, K. M. et al. Risk assessment of macrovascular and microvascular events in patients with Type 2 diabetes by analyzing the amplitude variation of the fourth harmonic component of radial pulse wave. Physiol. Rep. 7, e14252 (2019).
Lièvre, M. M. et al. Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening. Trials 12, 23 (2011).
Lim, L. L. et al. Sudomotor dysfunction independently predicts incident cardiovascular-renal events and all-cause death in Type 2 diabetes: the Joint Asia Diabetes Evaluation register. Nephrol. Dial. Transplant 34, 1320–1328 (2019).
Lim, S. et al. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis 196, 398–404 (2008).
Lin, C. H., Li, H. Y., Jiang, Y. D., Chang, T. J. & Chuang, L. M. Plasma YKL-40 predicts 10-year cardiovascular and all-cause mortality in individuals with Type 2 diabetes. Clin. Endocrinol. (Oxf) 79, 185–191 (2013).
Lin, E. H. et al. Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care 33, 264–269 (2010).
Lin, L. Y. et al. The ankle brachial index exhibits better association with cardiovascular outcomes than interarm systolic blood pressure difference in patients with type 2 diabetes. Medicine (Baltimore) 98, e15556 (2019).
Linnemann, B. & Janka, H. U. Prolonged QTc interval and elevated heart rate identify the Type 2 diabetic patient at high risk for cardiovascular death. The Bremen Diabetes Study. Exp. Clin. Endocrinol. Diabetes 111, 215–222 (2003).
Linnemann, B., Voigt, W., Nobel, W. & Janka, H. U. C-reactive protein is a strong independent predictor of death in Type 2 diabetes: association with multiple facets of the metabolic syndrome. Exp. Clin. Endocrinol. Diabetes 114, 127–134 (2006).
Lopes-Virella, M. F., Hunt, K. J., Baker, N. L., Virella, G. & Moritz, T. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis 224, 526–531 (2012).
Lorenzo-Almorós, A. et al. Galectin-3 is associated with cardiovascular events in post-acute coronary syndrome patients with Type-2 diabetes. J. Clin. Med. 9, 1105 (2020).
Lowe, G. et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with Type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes 63, 1115–1123 (2014).
Lu, T. M., Lin, S. J., Lin, M. W., Hsu, C. P. & Chung, M. Y. The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with Type 2 diabetes: a cohort study. Cardiovasc. Diabetol. 10, 16 (2011).
Lu, W. et al. Non-HDL cholesterol as a predictor of cardiovascular disease in Type 2 diabetes: the strong heart study. Diabetes Care 26, 16–23 (2003).
Lutgers, H. L. et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in Type 2 diabetes mellitus. Diabetologia 52, 789–797 (2009). 1308-9.
Masi, S. et al. Telomere length, antioxidant status and incidence of ischaemic heart disease in Type 2 diabetes. Int. J. Cardiol. 216, 159–164 (2016).
Massardo, T. et al. Factors associated with silent myocardial ischemia, autonomic or peripheral neuropathies, and survival in diabetes mellitus type 2 patients without cardiovascular symptoms. Int. J. Diabetes Developing Countries 40, 80–86 (2020).
McEwan, P., Bennett, H., Ward, T. & Bergenheim, K. Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK. Pharmacoeconomics 33, 149–161 (2015).
McMurray, J. J. et al. Predictors of fatal and nonfatal cardiovascular events in patients with Type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the trial to reduce cardiovascular events with aranesp (darbepoetin-alfa) therapy (TREAT). Am. Heart J. 162, 748–755.e743 (2011).
Meerwaldt, R. et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30, 107–112 (2007).
Mellbin, L. G. et al. Copeptin, IGFBP-1, and cardiovascular prognosis in patients with Type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care 33, 1604–1606 (2010).
Mentz, R. J. et al. Effect of once-weekly exenatide on clinical outcomes according to baseline risk in patients with Type 2 diabetes mellitus: insights from the EXSCEL trial. J. Am. Heart Assoc. 7, e009304 (2018).
Mohammedi, K. et al. Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with Type 1 and Type 2 diabetes. Cardiovasc. Diabetol. 14, 845 (2015).
Mohammedi, K. et al. Absence of peripheral pulses and risk of major vascular outcomes in patients with Type 2 diabetes. Diabetes Care 39, 2270–2277 (2016).
Monseu, M. et al. Acute kidney injury predicts major adverse outcomes in diabetes: synergic impact with low glomerular filtration rate and albuminuria. Diabetes Care 38, 2333–2340 (2015).
Moosaie, F. et al. Lp(a) and Apo-lipoproteins as predictors for micro- and macrovascular complications of diabetes: A case-cohort study. Nutr. Metab. Cardiovasc. Dis. 30, 1723–1731 (2020).
Morieri, M. L. et al. Genetic tools for coronary risk assessment in Type 2 diabetes: a Cohort study from the ACCORD clinical trial. Diabetes Care 41, 2404–2413 (2018).
Morrish, N. J., Stevens, L. K., Fuller, J. H., Jarrett, R. J. & Keen, H. Risk factors for macrovascular disease in diabetes mellitus: the London follow-up to the WHO multinational study of vascular disease in diabetics. Diabetologia 34, 590–594 (1991).
Mukamal, K. J. et al. Prediction and classification of cardiovascular disease risk in older adults with diabetes. Diabetologia 56, 275–283 (2013).
Nag, S. et al. All-cause and cardiovascular mortality in diabetic subjects increases significantly with reduced estimated glomerular filtration rate (eGFR): 10 years’ data from the South Tees Diabetes Mortality study. Diabet Med. 24, 10–17 (2007).
Nagamachi, S. et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J. Nucl. Cardiol. 13, 34–42 (2006).
Nakamura, M. et al. Brachial-ankle pulse wave velocity as a risk stratification index for the short-term prognosis of Type 2 diabetic patients with coronary artery disease. Hypertens Res. 33, 1018–1024 (2010).
Nam, G. E. et al. Body weight variability and the risk of cardiovascular outcomes and mortality in patients with Type 2 diabetes: a nationwide Cohort Study. Diabetes Care 43, 2234–2241 (2020).
Nargesi, A. A. et al. Nonlinear relation between pulse pressure and coronary heart disease in patients with Type 2 diabetes or hypertension. J. Hypertens. 34, 974–980 (2016).
Nazimek-Siewniak, B., Moczulski, D. & Grzeszczak, W. Risk of macrovascular and microvascular complications in Type 2 diabetes: results of longitudinal study design. J. Diabetes Complications 16, 271–276 (2002).
Ndrepepa, G. et al. Prognostic value of uric acid in patients with Type 2 diabetes mellitus and coronary artery disease. Clin. Sci. (Lond) 124, 259–268 (2013).
Nelson, R. G. et al. Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes. Circulation 81, 987–995 (1990).
Neves, A. L. et al. Allelic variations in superoxide dismutase-1 (SOD1) gene and renal and cardiovascular morbidity and mortality in Type 2 diabetic subjects. Mol. Genet. Metab. 106, 359–365 (2012).
Nichols, G. A., Joshua-Gotlib, S. & Parasuraman, S. Independent contribution of A1C, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: an observational cohort study. J. Gen. Intern. Med. 28, 691–697 (2013).
Nilsson, P. M. et al. Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register. Eur. J. Cardiovasc. Prev. Rehabil. 16, 506–512 (2009).
Ningshen, R., Odyuo, Moathung, Arvind, Z., Deba Singh, G. & Devi, T. S. B. A study of QTc interval prolongation as an independent predictor of cardiac mortality in type 2 diabetes mellitus. JMS – J. Med. Soc. 26, 21–25 (2012).
Niskanen, L., Turpeinen, A., Penttilä, I. & Uusitupa, M. I. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 21, 1861–1869 (1998).
Niskanen, L. K., Penttilã, I., Parviainen, M. & Uusitupa, M. I. Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. Diabetes Care 19, 486–493 (1996).
Nitenberg, A. et al. Cardiovascular outcome of patients with abnormal coronary vasomotion and normal coronary arteriography is worse in type 2 diabetes mellitus than in arterial hypertension: a 10 year follow-up study. Atherosclerosis 183, 113–120 (2005).
Novo-Rodríguez, C. et al. Circulating levels of sclerostin are associated with cardiovascular mortality. PLoS One 13, e0199504 (2018).
Odeberg, J., Larsson, C. A., Råstam, L. & Lindblad, U. The Asp298 allele of endothelial nitric oxide synthase is a risk factor for myocardial infarction among patients with Type 2 diabetes mellitus. BMC Cardiovasc. Disord 8, 36 (2008).
Oellgaard, J. et al. Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with Type 2-diabetes and microalbuminuria. J. Diabetes Complications 32, 1133–1140 (2018).
Oliveira, J. L. et al. Prognostic value of exercise echocardiography in diabetic patients. Cardiovasc. Ultrasound 7, 24 (2009).
Ong, K. L. et al. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia 58, 464–473 (2015).
Ong, K. L. et al. Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Res. Clin. Pract. 169, 108450 (2020).
Ortega Moreno, L. et al. Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes. Cardiovasc. Diabetol. 15, 17 (2016).
Oshima, M. et al. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE trial. J. Am. Soc. Nephrol. 31, 2925–2936 (2020).
Otto, S. et al. Microembolization and myonecrosis during elective percutaneous coronary interventions in diabetic patients: an intracoronary Doppler ultrasound study with 2-year clinical follow-up. Basic Res. Cardiol. 107, 289 (2012).
Pagidipati, N. J. et al. Association of obesity with cardiovascular outcomes in patients with Type 2 diabetes and cardiovascular disease: Insights from TECOS. Am. Heart J. 219, 47–57 (2020).
Panero, F. et al. Uric acid is not an independent predictor of cardiovascular mortality in Type 2 diabetes: a population-based study. Atherosclerosis 221, 183–188 (2012).
Park, G. M. et al. Coronary computed tomographic angiographic findings in asymptomatic patients with Type 2 diabetes mellitus. Am. J. Cardiol. 113, 765–771 (2014).
Peng, W. H. et al. Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients. Clin. Biochem. 42, 1252–1259 (2009).
Peters, K. E., Chubb, S. A., Davis, W. A. & Davis, T. M. The relationship between hypomagnesemia, metformin therapy and cardiovascular disease complicating type 2 diabetes: the Fremantle Diabetes Study. PLoS One 8, e74355 (2013).
Petretta, M. et al. Transient ischemic dilation in patients with diabetes mellitus: prognostic value and effect on clinical outcome after coronary revascularization. Circ. Cardiovasc. Imaging 6, 908–915 (2013).
Pfister, R., Cairns, R., Erdmann, E. & Schneider, C. A. Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive study. Diabet. Med. 28, 1206–1212 (2011).
Pickup, J. C. & Mattock, M. B. Activation of the innate immune system as a predictor of cardiovascular mortality in Type 2 diabetes mellitus. Diabet Med. 20, 723–726 (2003).
Piniés, J. A. et al. Development of a prediction model for fatal and non-fatal coronary heart disease and cardiovascular disease in patients with newly diagnosed type 2 diabetes mellitus: the Basque Country Prospective Complications and Mortality Study risk engine (BASCORE). Diabetologia 57, 2324–2333 (2014).
Pintó, X. et al. [Factors predictive of cardiovascular disease in patients with type-2 diabetes and hypercholesterolemia. ESODIAH study]. Rev Esp Cardiol 60, 251–258 (2007).
Poon, P. Y., Szeto, C. C., Kwan, B. C., Chow, K. M. & Li, P. K. Relationship between beta1-adrenergic receptor polymorphisms and cardiovascular disease in patients with diabetic nephropathy. Nephrology (Carlton) 15, 242–247 (2010).
Poon, P. Y., Szeto, C. C., Kwan, B. C., Chow, K. M. & Li, P. K. Relationship between HSP70-2 A+1267G polymorphism and cardiovascular events of Chinese peritoneal dialysis patients. Nephron Clin. Pract. 128, 153–158 (2014).
Porchay-Baldérelli, I. et al. The CETP TaqIB polymorphism is associated with the risk of sudden death in Type 2 diabetic patients. Diabetes Care 30, 2863–2867 (2007).
Porchay-Baldérelli, I. et al. Relationships between common polymorphisms of adenosine triphosphate-binding cassette transporter A1 and high-density lipoprotein cholesterol and coronary heart disease in a population with Type 2 diabetes mellitus. Metabolism 58, 74–79 (2009).
Prentice, J. C., Pizer, S. D. & Conlin, P. R. Identifying the independent effect of HbA1c variability on adverse health outcomes in patients with Type 2 diabetes. Diabetic Med. 33, 1640–1648 (2016).
Qi, L. et al. The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men. Diabetes 54, 1607–1610 (2005).
Qi, L. et al. Genetic susceptibility to coronary heart disease in type 2 diabetes: 3 independent studies. J. Am. Coll. Cardiol. 58, 2675–2682 (2011).
Qi, L. et al. Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes. JAMA 310, 821–828 (2013).
Qi, Q., Workalemahu, T., Zhang, C., Hu, F. B. & Qi, L. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of Type 2 diabetes. Eur. Heart J. 33, 325–334 (2012).
Qin, Z. et al. The atherogenic index of plasma plays an important role in predicting the prognosis of Type 2 diabetic subjects undergoing percutaneous coronary intervention: results from an observational cohort study in China. Cardiovasc. Diabetol. 19, 23 (2020).
Quan, J. et al. Risk prediction scores for mortality, cerebrovascular, and heart disease among Chinese people with Type 2 diabetes. J. Clin. Endocrinol. Metab. 104, 5823–5830 (2019).
Raghavan, S. et al. Diabetes mellitus-related all-cause and cardiovascular mortality in a National cohort of adults. J. Am. Heart Assoc. 8, e011295 (2019).
Ramírez-Prado, D. et al. A four-year cardiovascular risk score for Type 2 diabetic inpatients. PeerJ 2015, e984 (2015).
Rana, B. S. et al. QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function tests. Heart 91, 44–50 (2005).
Rasmussen, D. G. K. et al. Higher collagen VI formation is associated with all-cause mortality in patients with Type 2 diabetes and microalbuminuria. Diabetes Care 41, 1493–1500 (2018).
Ravassa, S. et al. Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with Type 2 diabetes mellitus: a pilot study. Free Radic. Biol. Med. 81, 1–12 (2015).
Rawshani, A. et al. Risk factors, mortality, and cardiovascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 379, 633–644 (2018).
Rawshani, A. et al. Association between socioeconomic status and mortality, cardiovascular disease, and cancer in patients with Type 2 diabetes. JAMA Intern Med 176, 1146–1154 (2016).
Read, S. H. et al. Performance of cardiovascular disease risk scores in people diagnosed with Type 2 diabetes: external validation using data from the National Scottish diabetes register. Diabetes Care 41, 2010–2018 (2018).
Reinhard, H. et al. Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 33, 2561–2566 (2010).
Resl, M. et al. Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus. Diabet. Med. 29, 721–725 (2012).
Resl, M. et al. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes. Heart 102, 1963–1968 (2016).
Rossi, M. C. et al. Quality of diabetes care predicts the development of cardiovascular events: results of the AMD-QUASAR study. Diabetes Care 34, 347–352 (2011).
Rotbain Curovic, V. et al. Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. Acta Diabetol. 55, 1143–1150 (2018).
Roumeliotis, A. et al. Carotid intima-media thickness is an independent predictor of all-cause mortality and cardiovascular morbidity in patients with diabetes mellitus Type 2 and chronic kidney disease. Ren Fail 41, 131–138 (2019).
Roumeliotis, A. K. et al. Association of ALOX12 gene polymorphism with all-cause and cardiovascular mortality in diabetic nephropathy. Int. Urol. Nephrol. 50, 321–329 (2018).
Roumeliotis, S. et al. Matrix Gla protein T-138C polymorphism is associated with carotid intima media thickness and predicts mortality in patients with diabetic nephropathy. J. Diabetes Complications 31, 1527–1532 (2017).
Rozing, M. P. et al. Changes in HbA1c during the first six years after the diagnosis of Type 2 diabetes mellitus predict long-term microvascular outcomes. PLoS One 14, e0225230 (2019).
Ruggenenti, P. et al. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with Type 2 diabetes. J. Am. Soc. Nephrol. 23, 1717–1724 (2012).
Russo, G. T. et al. Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductase gene and the risk of macroangiopathy in type 2 diabetes: a prospective study. Acta Diabetol 48, 95–101 (2011).
Rutter, M. K., Wahid, S. T., McComb, J. M. & Marshall, S. M. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with Type 2 diabetes. J. Am. Coll. Cardiol. 40, 56–61 (2002).
Rådholm, K. et al. The impact of using sagittal abdominal diameter to predict major cardiovascular events in European patients with Type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 27, 418–422 (2017).
Rørth, R. et al. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur. J. Heart Fail 21, 40–49 (2019).
Saely, C. H. et al. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J. Clin. Endocrinol. Metab. 90, 5698–5703 (2005).
Saely, C. H. et al. Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients. Eur. J. Clin. Invest. 36, 91–97 (2006).
Saito, I. et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann. Intern. Med. 133, 81–91 (2000).
Sakai, K. et al. Small dense low-density lipoprotein cholesterol is a promising biomarker for secondary prevention in older men with stable coronary artery disease. Geriatr. Gerontol. Int. 18, 965–972 (2018).
Salles, G. F., Leite, N. C., Pereira, B. B., Nascimento, E. M. & Cardoso, C. R. Prognostic impact of clinic and ambulatory blood pressure components in high-risk Type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. J. Hypertens 31, 2176–2186 (2013).
Satirapoj, B., Tasanavipas, P. & Supasyndh, O. Role of TCF7L2 and PPARG2 gene polymorphisms in renal and cardiovascular complications among patients with Type 2 diabetes: a Cohort Study. Kidney Dis. 5, 220–227 (2019).
Saulnier, P. J. et al. Urinary sodium concentration is an independent predictor of all-cause and cardiovascular mortality in a Type 2 diabetes Cohort Population. J. Diabetes Res. 2017, 5327352 (2017).
Savonitto, S. et al. Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. Diabetes Vasc. Dis. Res. 15, 14–23 (2018).
Schimke, K., Chubb, S. A. P., Davis, W. A. & Davis, T. M. E. Helicobacter pylori cytotoxin-associated gene-A antibodies do not predict complications or death in Type 2 diabetes: The Fremantle Diabetes Study. Atherosclerosis 212, 321–326 (2010).
Schulze, M. B. et al. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 27, 889–894 (2004).
Schulze, M. B. et al. Joint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with Type 2 diabetes. Diabetologia 47, 2129–2136 (2004).
Scirica, B. M. et al. Prognostic implications of biomarker assessments in patients with Type 2 diabetes at high cardiovascular risk: A secondary analysis of a randomized clinical trial. JAMA Cardiol. 1, 989–998 (2016).
Scirica, B. M. et al. Cardiovascular outcomes according to urinary albumin and kidney disease in patients with Type 2 diabetes at high cardiovascular risk: observations from the SAVOR-TIMI 53 trial. JAMA Cardiol 3, 155–163 (2018).
Seferovic, J. P. et al. Retinopathy, neuropathy, and subsequent cardiovascular events in patients with Type 2 diabetes and acute coronary syndrome in the ELIXA: the importance of disease duration. J. Diabetes Res. 2018, 1631263 (2018).
Seyoum, B., Estacio, R. O., Berhanu, P. & Schrier, R. W. Exercise capacity is a predictor of cardiovascular events in patients with Type 2 diabetes mellitus. Diabetes Vasc. Dis. Res. 3, 197–201 (2006).
Shao, H., Fonseca, V., Stoecker, C., Liu, S. & Shi, L. Novel risk engine for diabetes progression and mortality in USA: building, relating, assessing, and validating outcomes (BRAVO). Pharmacoeconomics 36, 1125–1134 (2018).
Shao, H., Shi, L. & Fonseca, V. A. Using the BRAVO risk engine to predict cardiovascular outcomes in clinical trials with sodium-glucose transporter 2 inhibitors. Diabetes Care 43, 1530–1536 (2020).
Sharma, A. et al. Causes of death in a contemporary Cohort of Patients With Type 2 diabetes and atherosclerotic cardiovascular disease: insights from the TECOS trial. Diabetes Care 40, 1763–1770 (2017).
Sharma, A. et al. Clinical and biomarker predictors of expanded heart failure outcomes in patients with Type 2 diabetes mellitus after a recent acute coronary syndrome: insights from the EXAMINE Trial. J. Am. Heart Assoc. 9, e012797 (2020).
Shin, S. H. et al. Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with Type 2 diabetes and a recent acute coronary syndrome. Eur. J. Heart Fail. 22, 1133–1143 (2020).
Siddique, A. et al. Relationship of mildly increased albuminuria and coronary artery revascularization outcomes in patients with diabetes. Catheter Cardiovasc. Interv. 93, E217–e224 (2019).
Sidorenkov, G., Voorham, J., de Zeeuw, D., Haaijer-Ruskamp, F. M. & Denig, P. Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes? PLoS One 8, e78821 (2013).
Silva, A. P. et al. Phosphorus as an early marker of morbidity and mortality in Type 2 chronic kidney disease diabetic patients. J. Diabetes Complications 27, 328–332 (2013).
Silva, A. P. et al. What is the role of apelin regarding cardiovascular risk and progression of renal disease in Type 2 diabetic patients with diabetic nephropathy? Biomed. Res. Int. 2013, 247649 (2013).
Simmons, R. K. et al. Performance of the UK prospective diabetes study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC- Norfolk Cohort. Diabetes Care 32, 708–713 (2009).
Smáradóttir, M. I. et al. Copeptin and insulin-like growth factor binding protein-1 during follow-up after an acute myocardial infarction in patients with type 2 diabetes: a report from the diabetes mellitus insulin-glucose infusion in acute myocardial infarction 2 cohort. Diab. Vasc. Dis. Res. 16, 22–27 (2019).
So, W. Y. et al. Aldose reductase genotypes and cardiorenal complications: an 8-year prospective analysis of 1074 Type 2 diabetic patients. Diabetes Care 31, 2148–2153 (2008).
Soejima, H. et al. Proteinuria is independently associated with the incidence of primary cardiovascular events in diabetic patients. J. Cardiol. 75, 387–393 (2020).
Soinio, M., Marniemi, J., Laakso, M., Lehto, S. & Rönnemaa, T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with Type 2 diabetes mellitus. Ann. Intern. Med. 140, 94–100, (2004).
Sone, H. et al. Waist circumference as a cardiovascular and metabolic risk in Japanese patients with Type 2 diabetes. Obesity (Silver Spring) 17, 585–592 (2009).
Sone, H. et al. Comparison of various lipid variables as predictors of coronary heart disease in Japanese men and women with Type 2 diabetes: subanalysis of the Japan Diabetes Complications Study. Diabetes Care 35, 1150–1157 (2012).
Sone, H. et al. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with Type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J. Clin. Endocrinol. Metab. 96, 3448–3456 (2011).
Sone, H. et al. Leisure-time physical activity is a significant predictor of stroke and total mortality in Japanese patients with Type 2 diabetes: analysis from the Japan Diabetes Complications Study (JDCS). Diabetologia 56, 1021–1030 (2013).
Spoelstra-de Man, A. M., Brouwer, C. B., Stehouwer, C. D. & Smulders, Y. M. Rapid progression of albumin excretion is an independent predictor of cardiovascular mortality in patients with Type 2 diabetes and microalbuminuria. Diabetes Care 24, 2097–2101 (2001).
Standl, E. et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 39, 1540–1545 (1996).
Stehouwer, C. D., Gall, M. A., Hougaard, P., Jakobs, C. & Parving, H. H. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int 55, 308–314 (1999).
Stevens, R. J., Kothari, V., Adler, A. I. & Stratton, I. M. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin. Sci. (Lond) 101, 671–679 (2001).
Strojek, K. et al. Factors associated with cardiovascular events in patients with Type 2 diabetes and acute myocardial infarction. J. Clin. Endocrinol. Metab. 101, 243–253 (2016).
Sultan, A. et al. Myocardial perfusion imaging and cardiac events in a cohort of asymptomatic patients with diabetes living in southern France. Diabet. Med. 23, 410–418 (2006).
Svendstrup, M., Christiansen, M. S., Magid, E., Hommel, E. & Feldt-Rasmussen, B. Increased orosomucoid in urine is an independent predictor of cardiovascular and all-cause mortality in patients with Type 2 diabetes at 10 years of follow-up. J. Diabetes Complications 27, 570–575 (2013).
Svensson, E. et al. Early glycemic control and magnitude of HbA(1c) reduction predict cardiovascular events and mortality: population-based Cohort Study of 24,752 metformin initiators. Diabetes Care 40, 800–807 (2017).
Svensson, M. K., Cederholm, J., Eliasson, B., Zethelius, B. & Gudbjörnsdottir, S. Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with Type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. Diab. Vasc. Dis. Res. 10, 520–529 (2013).
Takao, T., Suka, M., Yanagisawa, H. & Iwamoto, Y. Impact of postprandial hyperglycemia at clinic visits on the incidence of cardiovascular events and all-cause mortality in patients with Type 2 diabetes. J. Diabetes Investig. 8, 600–608 (2017).
Tan, X. & Benedict, C. Increased risk of myocardial infarction among patients with type 2 diabetes who carry the common rs10830963 variant in the MTNR1B gene. Diabetes Care 43, 2289–2292 (2020).
Tanaka, S. et al. Predicting macro- and microvascular complications in Type 2 diabetes: the Japan diabetes complications study/the Japanese elderly diabetes intervention trial risk engine. Diabetes Care 36, 1193–1199 (2013).
Thanyasiri, P., Celermajer, D. S. & Adams, M. R. Predictors of long-term outcome following percutaneous coronary intervention in patients with type 2 diabetes mellitus. Coron Artery Dis 17, 131–138 (2006).
The Look, A. R. G. Prospective association of a genetic risk score and lifestyle intervention with cardiovascular morbidity and mortality among individuals with type 2 diabetes: the Look AHEAD randomised controlled trial. Diabetologia 58, 1803–1813 (2015).
Theilade, S. et al. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia–the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). J. Hum. Hypertens. 30, 46–52 (2016).
Thomas, M. C. et al. Relationship Between Plasma 8-OH-Deoxyguanosine and Cardiovascular Disease and Survival in Type 2 Diabetes Mellitus: Results From the ADVANCE Trial. J. Am. Heart Assoc. 7, e008226 (2018).
Tian, P., Zheng, X., Li, M., Li, W. & Niu, Q. Long-term prognostic value of coronary computed tomography angiography for asymptomatic patients with cad in type 2 diabetes mellitus. Exp. Therap. Med. 18, 747–754 (2019).
Ting, R. Z. et al. Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovasc. Diabetol. 9, 77 (2010).
Tobias, D. K. et al. Circulating branched-chain amino acids and incident cardiovascular disease in a prospective Cohort of US women. Circ. Genom. Precis. Med. 11, e002157 (2018).
Turner, R. C. et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316, 823–828 (1998).
Twito, O. et al. New-onset diabetes in elderly subjects: association between HbA1c levels, mortality, and coronary revascularization. Diabetes Care 36, 3425–3429 (2013).
Umamahesh, K., Vigneswari, A., Surya Thejaswi, G., Satyavani, K. & Viswanathan, V. Incidence of cardiovascular diseases and associated risk factors among subjects with type 2 diabetes – an 11-year follow up study. Indian Heart J. 66, 5–10 (2014).
Valmadrid, C. T., Klein, R., Moss, S. E. & Klein, B. E. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch. Intern. Med. 160, 1093–1100 (2000).
Valoti, E. et al. Impact of a complement factor H Gene variant on renal dysfunction, cardiovascular events, and response to ACE inhibitor therapy in Type 2 diabetes. Front Genet 10, 681 (2019).
van der Heijden, A. A., Ortegon, M. M., Niessen, L. W., Nijpels, G. & Dekker, J. M. Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study. Diabetes Care 32, 2094–2098 (2009).
van der Leeuw, J. et al. Novel biomarkers to improve the prediction of cardiovascular event risk in Type 2 diabetes mellitus. J. Am. Heart Assoc. 5, e003048 (2016).
van der Leeuw, J. et al. The validation of cardiovascular risk scores for patients with Type 2 diabetes mellitus. Heart 101, 222–229 (2015).
Vanzetto, G. et al. Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography. Diabetes Care 22, 19–26 (1999).
Vavruch, C. et al. Using proximity extension proteomics assay to discover novel biomarkers associated with circulating leptin levels in patients with Type 2 diabetes. Sci. Rep. 10, 13097 (2020).
Velho, G. et al. Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of Type 2 diabetes. Cardiovasc. Diabetol. 17, 110 (2018).
Vengen, I. T., Dale, A. C., Wiseth, R., Midthjell, K. & Videm, V. Lactoferrin is a novel predictor of fatal ischemic heart disease in diabetes mellitus type 2: long-term follow-up of the HUNT 1 study. Atherosclerosis 212, 614–620 (2010).
Venskutonyte, L., Brismar, K., Öhrvik, J., Rydén, L. & Kjellström, B. Self-rated health predicts outcome in patients with Type 2 diabetes and myocardial infarction: a DIGAMI 2 quality of life sub-study. Diab. Vasc. Dis. Res. 10, 361–367 (2013).
Venskutonyte, L., Malmberg, K., Norhammar, A., Wedel, H. & Rydén, L. Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes. J. Intern. Med. 268, 75–82 (2010).
Venuraju, S. M. et al. Duration of Type 2 diabetes mellitus and systolic blood pressure as determinants of severity of coronary stenosis and adverse events in an asymptomatic diabetic population: PROCEED study. Cardiovasc. Diabetol. 18, 51 (2019).
Venuraju, S. M. et al. Association of epicardial fat volume with the extent of coronary atherosclerosis and cardiovascular adverse events in asymptomatic patients with diabetes. Angiology 72, 442–450 (2021).
Venäläinen, M. S., Klén, R., Mahmoudian, M., Raitakari, O. T. & Elo, L. L. Easy-to-use tool for evaluating the elevated acute kidney injury risk against reduced cardiovascular disease risk during intensive blood pressure control. J. Hypertens. 38, 511–518 (2020).
Vepsäläinen, T. et al. Proteinuria modifies the effect of systolic blood pressure on total and cardiovascular disease mortality in patients with type 2 diabetes. J. Intern. Med. 272, 611–619 (2012).
von Scholten, B. J. et al. Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with Type 2 diabetes. Cardiovasc. Diabetol. 14, 59 (2015).
von Scholten, B. J. et al. Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in Type 2 diabetic patients with microalbuminuria. Diabetologia 59, 1549–1557 (2016).
von Scholten, B. J. et al. Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. J Diabetes Complications 30, 248–255 (2016).
Wallander, M. et al. IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. Diabetes Care 30, 2343–2348 (2007).
Wan, E. Y., Fong, D. Y., Fung, C. S. & Lam, C. L. Incidence and predictors for cardiovascular disease in Chinese patients with Type 2 diabetes mellitus – a population-based retrospective cohort study. J. Diabetes Complications 30, 444–450 (2016).
Wan, E. Y. F. et al. Development of a cardiovascular diseases risk prediction model and tools for Chinese patients with Type 2 diabetes mellitus: A population-based retrospective cohort study. Diabetes Obes. Metab. 20, 309–318 (2018).
Wang, Y. et al. Independent predictive roles of eotaxin Ala23Thr, paraoxonase 2 Ser311Cys and beta-adrenergic receptor Trp64Arg polymorphisms on cardiac disease in Type 2 Diabetes–an 8-year prospective cohort analysis of 1297 patients. Diabet Med. 27, 376–383 (2010).
Wang, Y. et al. Prognostic effect of insertion/deletion polymorphism of the ace gene on renal and cardiovascular clinical outcomes in Chinese patients with Type 2 diabetes. Diabetes Care 28, 348–354 (2005).
Watson, C. et al. Investigation of association of genetic variant rs3918242 of matrix metalloproteinase-9 with hypertension, myocardial infarction and progression of ventricular dysfunction in Irish Caucasian patients with diabetes: a report from the STOP-HF follow-up prog. BMC Cardiovasc. Disord. 21, 87 (2021).
Wei, M., Gaskill, S. P., Haffner, S. M. & Stern, M. P. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 21, 1167–1172 (1998).
Wells, B. J. et al. Prediction of morbidity and mortality in patients with Type 2 diabetes. PeerJ 2013, e87 (2013).
Wijkman, M., Länne, T., Östgren, C. J. & Nystrom, F. H. Aortic pulse wave velocity predicts incident cardiovascular events in patients with type 2 diabetes treated in primary care. J. Diabetes Complications 30, 1223–1228 (2016).
Wijkman, M., Länne, T., Östgren, C. J. & Nystrom, F. H. Diastolic orthostatic hypertension and cardiovascular prognosis in Type 2 diabetes: a prospective cohort study. Cardiovasc. Diabetol. 15, 83 (2016).
Winkler, K. et al. Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with Type 2 diabetes mellitus. Atherosclerosis 208, 197–202 (2010).
Wolsk, E. et al. Role of B-Type natriuretic peptide and N-Terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and Type 2 diabetes mellitus. J. Am. Heart Assoc. 6, e004743 (2017).
Wong, Y. K. et al. High-sensitivity troponin I and B-type natriuretic peptide biomarkers for prediction of cardiovascular events in patients with coronary artery disease with and without diabetes mellitus. Cardiovasc. Diabetol. 18, 171 (2019).
Woodward, M. et al. Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score. Diabetes Obes. Metab. 18, 289–294 (2016).
Yamada, T., Itoi, T., Kiuchi, Y., Nemoto, M. & Yamashita, S. Proliferative diabetic retinopathy is a predictor of coronary artery disease in Japanese patients with type 2 diabetes. Diabetes Res. Clin. Pract. 96, e4–6 (2012).
Yamasaki, Y. et al. Carotid intima-media thickness in Japanese Type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease. Diabetes Care 23, 1310–1315 (2000).
Yang, F., Ye, J., Pomerantz, K. & Stewart, M. Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trials. Diabetes, Metab. Syndrome Obesity: Targets Ther. 6, 247–256 (2013).
Yang, G. R. et al. Association between neck circumference and the occurrence of cardiovascular events in Type 2 diabetes: Beijing Community Diabetes Study 20 (BCDS-20). Biomed. Res. Int. 2019, 4242304 (2019).
Yang, S. H. et al. Triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular events in diabetics with coronary artery disease. Am. J. Med. Sci. 354, 117–124 (2017).
Yang, S. H. et al. Serum fibrinogen and cardiovascular events in Chinese patients with Type 2 diabetes and stable coronary artery disease: a prospective observational study. BMJ Open 7, e015041 (2017).
Yang, X. et al. Impacts of chronic kidney disease and albuminuria on associations between coronary heart disease and its traditional risk factors in type 2 diabetic patients – the Hong Kong diabetes registry. Cardiovasc. Diabetol. 6, 37 (2007).
Yang, X. et al. Development and validation of a total coronary heart disease risk score in Type 2 diabetes mellitus. Am. J. Cardiol. 101, 596–601 (2008).
Yang, Z. K. et al. Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with Type 2 diabetes and stable coronary artery disease. Int. J. Cardiol. 197, 241–247 (2015).
Yeboah, J. et al. Development of a new diabetes risk prediction tool for incident coronary heart disease events: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. Atherosclerosis 236, 411–417 (2014).
Yeboah, P., Hsu, F. C., Bertoni, A. G. & Yeboah, J. Body mass index, change in weight, body weight variability and outcomes in Type 2 diabetes mellitus (from the ACCORD Trial). Am. J. Cardiol. 123, 576–581 (2019).
Yiu, K. H. et al. Predictive value of high-sensitivity troponin-I for future adverse cardiovascular outcome in stable patients with type 2 diabetes mellitus. Cardiovasc. Diabetol. 13, 63 (2014).
Yoshida, M. et al. Combination of the Framingham risk score and carotid intima-media thickness improves the prediction of cardiovascular events in patients with Type 2 diabetes. Diabetes Care 35, 178–180 (2012).
Yoshimura, T. et al. Low blood flow estimates in lower-leg arteries predict cardiovascular events in Japanese patients with Type 2 diabetes with normal ankle-brachial indexes. Diabetes Care 29, 1884–1890 (2006).
Young, J. B. et al. Development of predictive risk models for major adverse cardiovascular events among patients with Type 2 diabetes mellitus using health insurance claims data. Cardiovasc. Diabetol. 17, 118 (2018).
Yu, D. et al. Development and external validation of risk scores for cardiovascular hospitalization and rehospitalization in patients with diabetes. J. Clin. Endocrinol. Metab. 103, 1122–1129 (2018).
Yu, D. et al. Total/high density lipoprotein cholesterol and cardiovascular disease (re)hospitalization nadir in type 2 diabetes. J. Lipid Res. 59, 1745–1750 (2018).
Yu, D. et al. Derivation and external validation of a risk prediction algorithm to estimate future risk of cardiovascular death among patients with Type 2 diabetes and incident diabetic nephropathy: prospective cohort study. BMJ Open Diabetes Res Care 7, e000735 (2019).
Yu, D. & Simmons, D. Relationship between HbA1c and risk of all-cause hospital admissions among people with Type 2 diabetes. Diabetic Medicine 30, 1407–1411 (2013).
Yu, D. & Simmons, D. Association between blood pressure and risk of cardiovascular hospital admissions among people with type 2 diabetes. Heart 100, 1444–1449 (2014).
Yun, J. S., Park, Y. M., Cha, S. A., Ahn, Y. B. & Ko, S. H. Progression of cardiovascular autonomic neuropathy and cardiovascular disease in type 2 diabetes. Cardiovasc. Diabetol. 17, 109 (2018).
Zafrir, B. et al. Low cardiorespiratory fitness and coronary artery calcification: Complementary cardiovascular risk predictors in asymptomatic Type 2 diabetics. Atherosclerosis 241, 634–640 (2015).
Zafrir, B. et al. Resting heart rate and measures of effort-related cardiac autonomic dysfunction predict cardiovascular events in asymptomatic type 2 diabetes. Eur. J. Prev. Cardiol. 23, 1298–1306 (2016).
Zethelius, B. et al. A new model for 5-year risk of cardiovascular disease in Type 2 diabetes, from the Swedish National Diabetes Register (NDR). Diabetes Res. Clin. Pract. 93, 276–284 (2011).
Zhang, C. et al. Genetic variation in the hepatic lipase gene and the risk of coronary heart disease among US diabetic men: potential interaction with obesity. Diabetologia 49, 1552–1559 (2006).
Zhang, X. L. et al. Improved framingham risk scores of patients with Type 2 Diabetes Mellitus in the Beijing Community: A 10-Year prospective study of the effects of multifactorial interventions on cardiovascular risk factors (The Beijing Communities Diabetes Study 22). Diabetes Therapy 11, 885–903 (2020).
Zhao, Q. et al. Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China. Cardiovasc. Diabetol. 19, 108 (2020).
Zhou, J. B. et al. Prediction of proliferative diabetic retinopathy to asymptomatic obstructive coronary artery disease in Chinese Type 2 diabetes individuals: an exploratory study. Metab. Syndr. Relat. Disord. 17, 367–373 (2019).
Zimering, M. B., Anderson, R. J., Ge, L. & Moritz, T. E. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism 60, 284–291 (2011).
Zimering, M. B., Anderson, R. J., Ge, L., Moritz, T. E. & Duckworth, W. C. Basic fibroblast growth factor predicts cardiovascular disease occurrence in participants from the veterans affairs diabetes trial. Fronti. Endocrinol. 4, 183 (2013).
Zobel, E. H. et al. Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria. Diabetologia 60, 1883–1891 (2017).
Zoppini, G. et al. Usefulness of the triglyceride to high-density lipoprotein cholesterol ratio for predicting mortality risk in type 2 diabetes: role of kidney dysfunction. Atherosclerosis 212, 287–291 (2010).
Østergaard, H. B. et al. Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients. Diabetes Metab. 45, 254–260 (2019).
Fitipaldi, H. hugofitipaldi/T2DCVD_Prognostics: T2DCVD-Prognostics Shiny app. Zenodo, https://doi.org/10.5281/zenodo.10277173 (2023).
Fitipaldi, H. & Franks, P. W. Ethnic, gender and other sociodemographic biases in genome-wide association studies for the most burdensome non-communicable diseases: 2005-2022. Hum. Mol. Genet. 32, 520–532 (2023).
Misra, S. et al. Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. Lancet Diabetes Endocrinol. 9, 671–680 (2021).
Di Angelantonio, E. et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 120, 2177–2187 (2009).
Tam, C. H. T. et al. Identification of a common variant for coronary heart disease at PDE1A contributes to individualized treatment goals and risk stratification of cardiovascular complications in Chinese patients with Type 2 diabetes. Diabetes Care 46, 1271–1281 (2023).
Chan, J. et al. The Joint Asia Diabetes Evaluation (JADE) Program: a web-based program to translate evidence to clinical practice in Type 2 diabetes. Diabet Med. 26, 693–699 (2009).
Chan, J. C. N. et al. Effect of a web-based management guide on risk factors in patients with Type 2 diabetes and diabetic kidney disease: A JADE randomized clinical trial. JAMA Netw. Open 5, e223862 (2022).
Lim, L. L. et al. Association of technologically assisted integrated care with clinical outcomes in Type 2 diabetes in Hong Kong using the prospective JADE program: a retrospective cohort analysis. PLoS Med. 17, e1003367 (2020).
Chan, J. C. et al. Effects of telephone-based peer support in patients with type 2 diabetes mellitus receiving integrated care: a randomized clinical trial. JAMA Intern Med. 174, 972–981 (2014).
Lim, L. L. et al. Effects of a technology-assisted integrated diabetes care program on cardiometabolic risk factors among patients with Type 2 Diabetes in the Asia-Pacific Region: the JADE program randomized clinical trial. JAMA Netw. Open 4, e217557 (2021).